No Data
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $14
Ironwood Pharmaceuticals: Stability and Growth Potential Amid Internal Control Improvements
Ironwood Pharmaceuticals | 10-K: FY2024 Annual Report
Express News | Ironwood Pharmaceuticals Receives Letter Of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com